Caterina Brindicci

As Global Head of Respiratory & Immunology Late-Stage Development, I work with experts across biometrics, regulatory affairs, clinical operations, and clinical development. Together, we advance potential medicines from phase IIb through to submission and approval, and subsequently into life cycle management.

Despite important advances in recent years, there continues to be significant unmet need across respiratory and immunology diseases – from conditions like asthma and COPD affecting millions across the globe, to rare diseases with limited treatment options.

I joined AstraZeneca in 2022 and have been struck by the outstanding commitment to pushing the boundaries of science to transform care for people living with respiratory and immunology-based diseases. It is our ambition to move beyond symptom management towards disease modification and remission. Science thrives in an environment of true collaboration, so I am so pleased to see the innovative partnerships at play, both within AstraZeneca and externally, to help us realise this ambition.